← Back to headlines
AbbVie's Skyrizi and Rinvoq Drive Growth Amid Humira Decline
AbbVie's growth is being fueled by the strong performance of its drugs Skyrizi and Rinvoq, even as sales of its long-standing blockbuster Humira continue to decline.
31 Jul, 12:08 — 31 Jul, 12:08
Sources
Showing 1 of 1 sources
Related Stories
Asian Markets Fall and Oil Prices Rise Amid Escalating US-Iran Tensions
1h ago
US Treasury Secretary Urges Bank of Japan to Maintain Sound Monetary Policy Amid Yen Volatility
1h ago
Apple Sets Executive Pay for New CEO John Ternus and Chair Tim Cook
1h ago
BOJ to debate rate rise, inflation much closer to 2% target: governor
2h ago